Boletín de AInvest
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
AbbVie (ABBV) shares fell 3.14% on April 10, 2025, with a trading volume of $23.77 billion, ranking 34th in the day's market activity.
Wells Fargo analyst Mohit Bansal maintained a Buy rating on
, setting a price target of $240.00. This rating reflects the firm's confidence in the company's future performance and growth prospects.Morgan Stanley has also raised its price target for AbbVie to $241 from $239, indicating a positive outlook on the company's stock. This adjustment suggests that analysts are optimistic about AbbVie's potential for growth and profitability.
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Comentarios
Aún no hay comentarios